AtCor Medical Announces Breaking Study Supports Noninvasive Central Blood Pressure as a Treatment Target
NIH Funded Study Finds Cardiovascular Events Increase Significantly When Central Pulse Pressure Exceeds 50 mmHg
ITASCA, IL -- (Marketwire) -- 11/13/08 -- AtCor Medical (ASX: ACG), the developer andmarketer of the SphygmoCor® system, which measures central bloodpressures and arterial stiffness noninvasively, today announced that a newstudy* funded by the National Institutes of Health (NIH) found that whenpatients' central pulse pressures exceeded 50 mm of mercury, there was asignificant increase in cardiovascular events. The 2,405 patient study waspresented on November 12 at the 2008 American Heart Association ScientificSessions in New Orleans.
Central pulse pressure as a treatment target
Study participants were initially free of cardiovascular disease and werefollowed for a period of 5.5 years. During the course of the study, over340 participants experienced a major cardiovascular event. The studyabstract concluded that central pulse pressure equal to or greater than 50mm of mercury predicts adverse cardiovascular outcomes independent of otherrisk factors for cardiovascular disease. It further stated that thesefindings call for examination of noninvasive central pulse pressure as atreatment target in clinical intervention strategies.
"This is a major development," said Duncan Ross, AtCor Medical's Presidentand CEO. "Many studies have shown that elevated central blood pressure isassociated with increased incidence of heart attack, stroke and kidneydisease. This research identifies a specific central blood pressurethreshold where events sharply increase -- identifying patients at risk whowould not be identified with standard cuff blood pressure measurementstaken at the arm. The data from this study will be vitally important toclinicians in diagnosis and drug therapy management -- and inpharmaceutical trials."
About AtCor Medical
AtCor Medical develops and markets products for the early detection ofcardiovascular risk and management of cardiovascular disease. Itstechnology allows researchers and clinicians to measure central bloodpressure noninvasively. The company's SphygmoCor system visibly identifiesthe effects of reflected blood pressure in the central aortic pressurewave, effects which cannot be detected with standard blood pressuremonitoring. More than 1,700 SphygmoCor systems are currently in useworldwide at major medical centers, research institutions and in variousclinical trials with leading pharmaceutical companies. The company'stechnology has been featured in over 400 peer-reviewed studies published inleading medical journals. AtCor has operations in Australia, the UnitedStates and Europe. For further information, please visit our web site atwww.atcormedical.com.
*Mary J. Roman et al. Central Pulse Pressure 50mmHg Predicts AdverseCardiovascular Outcome: The Strong Heart Study Circulation.2008;118:S_1157
For further information, please contact:Larry WattsAtCor Medical630-228-8875l.watts@atcormedical.com
- 1 Digital Photo Frame Market Will Get Connected
- 2 Priceless Legacy Company Appoints Julie Davis to Legacy Consultant Position in Nebraska and Iowa
- 3 Koko the Gorilla Celebrates 38th Birthday, Makes Three Wishes
- 4 New Website Provides A Free List Of The Top Ten Chicago Real Estate Deals
- 5 Warrior Custom Golf Assists the Orange County United Way 2009 Fundraising Campaign
- 6 Kerching Online Casino Competition Winner Revealed
- 7 MyFirePits.com Announces Grand Opening
70% Profit in Less Than an Hour
Take profit from the markets roller coaster. No downloads, no commissions, no spreads.
Option Trading Was Never So Easy
Come and experience the trading platform that everyone talks about. Simple, fast and exciting.
Forex trading is too complicated?
Can predict currency pairs movements? Binary option trading is what you need. Click here.









